Research and innovation from EHL BIO

• ADSTEM Inj.

  Cell source

  Autologous adipose-derived mesenchymal stem cells

  Target indication

  Moderate to severe subacute and chronic atopic dermatitis

  Stage as stated

  Phase 1 completed (2017), Phase 2 completed (2023), Phase 3 IND submitted in 2024

  EHL BIO — Stem cell treatment

• KDSTEM Inj.

  Cell source

  Autologous urine-derived mesenchymal stem cells

  Target indication

  Chronic renal failure / chronic kidney disease

  Stage as stated

  IND approved and Phase 1 initiated in 2023; selected for the KFRM programme in 2022 and 2024

  EHL BIO — Stem cell treatment

• RASTEM Inj.

  Cell source

  Autologous adipose-derived mesenchymal stem cells

  Target indication

  Moderate or more severe rheumatoid arthritis

  Stage as stated

  The source page states the non-clinical study is being completed and a clinical trial is in preparation

  EHL BIO — Stem cell treatment

• PDSTEM Inj.

  Cell source

  Autologous adipose-derived mesenchymal stem cells

  Target indication

  Parkinson's disease

  Stage as stated

  The source page states it is in non-clinical progress

  EHL BIO — Stem cell treatment

• Keycell-IM Inj.

  Cell source

  Autologous peripheral blood immune cells (T, NK, iNKT and dendritic cells)

  Target indication

  Cancer immunotherapy research

  Stage as stated

  The hospital's affiliated research centre states NK cells completed preclinical study, with lung cancer as the target disease

  EHL BIO — Immune Cell Therapeutics

• ADSC exosome

  Cell source

  Exosomes from adipose-derived stem cells

  Target indication

  Neuropathic pain

  Stage as stated

  The source page states animal testing is in progress for patent application, with research on complex pain syndrome

  EHL BIO — Other treatments

• Novel thiazolidinedione derivatives and uses thereof

  Registration date: 2 Aug 2012 · No. 10-1172638

  States activity inhibiting 15-PGDH, which breaks down prostaglandin, so it may be used to prevent or treat cardiovascular, gastrointestinal and kidney disease, and to prevent hair loss and promote hair growth (as described in the patent).

• Composition comprising cells treated with a 15-PGDH inhibitor or culture thereof and use thereof

  Registration date: 27 Oct 2016 · No. 15771853

• Liposuction and SVF separation kit

  Registration date: 20 Jan 2016 · No. 10-2016-0007049

  Intended to facilitate fat collection and the series of processes for separating adipose-derived stem cells.

• Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof

  Registration date: 26 Oct 2016 · No. 10-2016-0139967

  Pharmaceutical composition for preventing or treating atopic disease, using cells cultured with a 15-PGDH inhibitor in PGE2-expressing cells or their culture (atopic dermatitis).

• Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof

  Registration date: 4 Jan 2018 · No. 10-2018-0001149

  Same family of pharmaceutical composition, with the indication stated as rheumatoid arthritis.

• Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof

  Registration date: 16 Mar 2018 · No. 10-2018-0030906

  Pharmaceutical composition for preventing or treating atopic disease (atopic dermatitis).

• Method for mass culturing adipose-derived stem cells expressing FoxO

  Registration date: 28 Dec 2018

  Related to a composition comprising cells treated with a 15-PGDH inhibitor or their culture and its use.

• Medium composition for culturing urine-derived stem cells and method for culturing them

  Registration date: 4 Nov 2019 · No. 10-2019-0139702

  Culture medium for isolating and culturing urine-derived stem cells, and a method for separating and culturing them using that medium.

• Mass culture method of adipose-derived stem cells expressing anti-ageing factors

  Registration date: 3 Feb 2020 · No. 10-2020-0012437

  Mass culture method for adipose-derived stem cells expressing Foxo1, Foxo3a and Klotho, with a medium composition for their proliferation and culture.

• Composition for skin regeneration, whitening, antioxidant or wound treatment comprising stem cell-derived exosomes

  Registration date: 17 Feb 2021 · No. 10-2021-0021026

  Cosmetic or pharmaceutical composition with urine-derived stem cell exosomes as the active ingredient.

• Medium composition and method for isolating and culturing urine-derived stem cells with improved renal-disease function, and a cell therapeutic composition

  Registration date: 29 Sept 2021 · No. 10-2021-0129299

  Covers the culture medium, the isolation and culture method, the resulting cells, and a cell therapeutic composition comprising them.

Certificates and trademarks

• EHLBio Research Institute certification
• European EHLBio trademark
• Indonesian EHLBio trademark rights
• 키셀 trademark registration certificate
• Kissel trademark registration certificate

Research papers listed by the hospital

• Human adipose tissue derived mesenchymal stem cells alleviate atopic dermatitis via regulation of B lymphocyte maturation

  19 Nov 2016

• Human Adipose Tissue Derived Mesenchymal Stem Cells Attenuate Atopic Dermatitis by Regulating the Expression of MIP2, miR122a-SOCS1 Axis, and Th1/Th2 Responses

  6 Nov 2018

• Urine-Derived Stem Cell-Secreted Klotho Plays a Crucial Role in the HK-2 Fibrosis Model by Inhibiting the TGF-β Signaling Pathway

  30 Apr 2022

• Production enhancement of human adipose-derived mesenchymal stem cells by low-intensity ultrasound stimulation

  21 Dec 2022

• In vivo safety and biodistribution profile of Klotho-enhanced human urine-derived stem cells for clinical application

  10 Dec 2023

• Combinational Pulsing of TAAs Enforces Dendritic Cell-Based Immunotherapy through T-Cell Proliferation and Interferon-γ Secretion in LLC1 Mouse Model

  18 Jan 2024